OREANDA-NEWS.  Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announces the launch of their new 'Chemical and Cosmetics Testing' guide.  The guide is focused in the field of chemical (including pesticides and industrial chemicals) and cosmetics testing and covers an overview of the US and EU legislation/guidance, as well as chapters on Integrated Testing Approaches, Skin Testing, Ocular Testing, Mutagenicity/Genotoxicity Testing and Endocrine Disruption Testing. 

Cyprotex has considerable expertise in this field since its acquisition of the business and assets of CeeTox, Inc in January 2014. This facility, which now forms part of the subsidiary Cyprotex US, LLC, is based in Kalamazoo in Michigan in the USA. It specialises in chemical and cosmetic testing approaches and can perform these studies under Good Laboratory Practice (GLP), which can be a requirement when submitting the data to the regulatory authorities. 

Sharing of knowledge and experience is a key part of Cyprotex's social responsibility policy. The new 'Chemical and Cosmetics Testing' guide complements Cyprotex's existing 'Everything you need to know about ADME', 'DDI Regulatory Guidance' and 'Mechanisms of Drug-Induced Toxicity' guides. The guides, which are extremely popular with customers, academic institutions and investors alike, provide a valuable resource for scientists in a range of disciplines who want to have an up-to-date overview of the current legislation and testing methods. 

Anthony Baxter PhD, Chief Executive Officer of Cyprotex, commented:

'The chemical and cosmetics industries are undergoing considerable change. This has been led by the European Cosmetics Directive which, in 2013, enforced a complete ban on animal testing for finished cosmetic products and ingredients. The introduction of REACH (an EU Regulation concerning the risks from chemicals) in 2007 has also meant that alternative non-animal methods are being encouraged to reduce the impact on animal testing requirements. Through our experience in in vitro testing approaches, we can assist our customers in meeting these changes in legislation and help to reduce the burden on animal testing.'

About Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX).  It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US.  The Company was established in 1999 and works with more than 1300 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, bioscience services, predictive modelling solutions including Cloe® PK, chemPK™ and chemTox, and a range of skin, ocular and endocrine disruption services.